Fig. 2From: Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potentialCharacterization of humanized Nb1-IgG4 (HuNb1-IgG4). a CDRs sequences of HuNb1-IgG4 were shown. b The activity of HuNb1-IgG4 binding to hCD47 on the surface of cells was determined by FACS. c The activity of HuNb1-IgG4 blocking CD47/SIRPĪ± was determined by FACS. d The specificity of HuNb1 to human CD47, mouse CD47 and rat CD47 antigen was detected by ELISA. The above experiments were performed in triplicate and data were presented as meanāĀ±āSD. ***Pā<ā0.001 versus control. e The affinity of B6H12 and HuNb1-IgG4 to CD47 was detected by Fortebio detection. The experiment was performed in triplicate and one representative experiment was shownBack to article page